Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 135

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 135
---
, and other factors described under “Risk Factors” in this prospectus, as well as the amount of cash used in our
operations and any unforeseen cash needs. We may find it necessary or advisable to use the net proceeds for other purposes, and our management will have broad discretion in the application of the net proceeds, and investors will be relying on our
judgment regarding the application of the net proceeds from this offering. In addition, we might decide to postpone or not pursue clinical trials or preclinical activities if the net proceeds from this offering and the other sources of cash are less
than expected.

Pending the use of the proceeds from this offering, we plan to invest the proceeds in short- and intermediate-term,
interest-bearing obligations, investment-grade instruments, certificates of deposit, or direct or guaranteed obligations of the U.S. government.

87

DIVIDEND POLICY

We have never declared or paid any cash dividends on our capital stock. We currently intend to retain all available funds and future earnings,
if any, to support our operations and finance the growth and development of our business. We have no present intention to pay cash dividends on our common stock for the foreseeable future. Any future determination related to our dividend policy will
be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, contractual restrictions (including any restrictions in our then-existing debt
arrangements), business prospects, and other factors our board of directors may deem relevant, and subject to the restrictions contained in any future financing instruments.

88

CAPITALIZATION The following table sets forth our cash and cash equivalents and marketable securities and our capitalization as of June 30, 2025:

| • |     | on an actual basis; |

| • |     | on a pro forma basis to reflect (i) the conversion of all outstanding shares of our redeemable convertible                                                                                                                                    
 preferred stock into 3,181,815 shares of our common stock and the related reclassification of the carrying value of the redeemable convertible preferred stock to stockholders’ equity upon the closing of this offering, and (ii) the filing 
 of our amended and restated certificate of incorporation immediately prior to the closing of this offering; and                                                                                                                               |

| • |     | on a pro forma as adjusted basis to reflect (i) the pro forma adjustments set forth above, (ii) our                                                                                                                                                    
 issuance and sale of 16,666,667 shares of common stock in this offering at